Core Insights - Merck's PD-1 monoclonal antibody, Keytruda, has achieved global sales exceeding $20 billion in both 2023 and 2024, solidifying its position as the leading drug in the lung cancer market [1] Industry Overview - Lung cancer remains the leading cause of cancer globally, with 2.4 million new cases each year, and China reporting significantly higher new cases than other countries [3] - The rise of targeted and immunotherapy treatments has transformed the treatment landscape for lung cancer, with new therapies such as ADCs, bispecific antibodies, and tumor vaccines expanding treatment options [3] Competitive Landscape - A race is underway among pharmaceutical companies to establish the next generation of immunotherapy leaders in lung cancer, with companies like Junshi Biosciences, Kintor Pharmaceutical, and Innovent Biologics actively competing [2][3] - Junshi Biosciences has reported promising results for its PD-L1 ADC, HLX43, showing an objective response rate (ORR) of 33.3% in squamous non-small cell lung cancer (NSCLC) patients and 48.6% in non-squamous patients [2] - Kintor Pharmaceutical's PD-1/VEGF bispecific antibody, Ivoris, is currently undergoing eight pivotal phase III clinical trials [5] - Innovent Biologics has announced a collaboration with Takeda Pharmaceutical to co-develop a new generation of immunotherapy, IBI363, which targets PD-1 and IL-2α [6] Clinical Development - Junshi Biosciences plans to initiate at least eight phase III clinical trials for HLX43 in the lung cancer space, with additional studies planned for cervical cancer, esophageal squamous cancer, and colorectal cancer [2][7] - The cost of each global phase III clinical trial is estimated to be around $200 million, presenting a significant financial challenge for companies [7] Financial Performance - Junshi Biosciences reported revenue of 2.82 billion yuan in the first half of the year, a year-on-year increase of 2.7%, with net profit remaining stable at 390 million yuan [7]

Core Viewpoint - Merck's PD-1 monoclonal antibody, Keytruda, has achieved over $20 billion in annual sales in both 2023 and 2024, solidifying its position as the global leader in the lung cancer treatment market [3]. Group 1: Company Updates - Jun Zhu, CEO of Junshi Biosciences, announced plans for at least eight Phase III clinical trials for HLX43, a PD-L1 ADC targeting non-small cell lung cancer (NSCLC) [5]. - HLX43 demonstrated an objective response rate (ORR) of 33.3% and a disease control rate (DCR) of 75.8% in squamous NSCLC patients, with ORR rising to 48.6% and DCR reaching 94.3% in non-squamous patients [4]. - Junshi Biosciences reported a revenue of 2.82 billion yuan in the first half of the year, a 2.7% increase year-on-year, with a net profit of 390 million yuan, remaining stable compared to the previous year [10]. Group 2: Industry Trends - The competition for the next generation of immune therapies in lung cancer is intensifying, with companies like Junshi Biosciences, Kintor Pharmaceutical, and Innovent Biologics all vying for leadership [6]. - The rise of targeted and immune therapies has reshaped the treatment landscape for lung cancer, expanding the boundaries of treatment options from ADCs to bispecific antibodies and tumor vaccines [5]. - Kintor Pharmaceutical is advancing its PD-1/VEGF bispecific antibody, Ivorin, with plans for eight Phase III clinical studies, while Innovent Biologics is collaborating with Takeda Pharmaceutical on a new generation immune therapy, IBI363 [8].

Core Viewpoint - The Guangdong-Hong Kong-Macao Greater Bay Area (GBA) is a highly open and economically vibrant region in China, contributing approximately 1/9 of the national economic output with only 0.6% of the country's land area [1][2]. Group 1: Innovation and R&D - The GBA has emerged as a leading innovation hub, with the Shenzhen-Hong Kong-Guangzhou innovation cluster ranking first in the World Intellectual Property Organization's "World's Top 100 Innovation Clusters" [4]. - In the first three quarters of this year, GBA listed companies invested a total of 237.31 billion yuan in R&D, accounting for 20.69% of all A-share companies' R&D expenses, indicating that 1 out of every 5 yuan spent on R&D in the A-share market comes from the GBA [4]. - BYD leads all A-share companies with R&D expenses of 43.75 billion yuan, focusing on advanced technologies such as fast-charging batteries and next-generation power chips [4]. Group 2: Industry Upgrading and New Growth Areas - The GBA is a key player in nurturing new productive forces, achieving breakthroughs in emerging sectors such as autonomous driving, low-altitude economy, and robotics [7]. - Companies like WeRide and Pony.ai have successfully listed on the Hong Kong Stock Exchange, with WeRide operating in 30 cities across 11 countries and Pony.ai focusing on local operations [7]. - The establishment of the "Air-Ground Integrated Smart AI Ecosystem Alliance" indicates a significant market potential in the low-altitude economy and robotics, projected to exceed one trillion yuan in the next five years [7]. Group 3: Global Expansion - GBA listed companies are increasingly pursuing internationalization, with total overseas revenue reaching 955.60 billion yuan in the first half of 2025, accounting for 19.5% of all A-share companies' overseas revenue [11]. - BYD achieved overseas revenue of 135.36 billion yuan, marking a 50.49% year-on-year increase, and has ambitious plans for further international expansion [11]. - Transsion Holdings has captured over 40% of the African smartphone market by focusing on differentiated imaging technology, showcasing a successful model for international market penetration [12]. Group 4: Upcoming Events - The 20th China Economic Forum will take place on November 18 in the Nansha Economic and Technological Development Zone, focusing on technology innovation and financial integration [17][18].

Core Insights - The competition for the next generation of immune therapies in lung cancer is intensifying, with various pharmaceutical companies vying for leadership in this lucrative market [2][3]. Group 1: Market Dynamics - Merck's PD-1 monoclonal antibody, Keytruda, has achieved over $20 billion in annual sales in both 2023 and 2024, solidifying its position as a market leader in lung cancer treatment [1]. - Lung cancer remains the leading cause of cancer globally, with 2.4 million new cases each year, and China contributing significantly to this figure [3]. Group 2: Clinical Developments - Jun Zhu, CEO of Junshi Biosciences, highlighted the promising results of HLX43, a PD-L1 ADC, showing an objective response rate (ORR) of 33.3% in squamous non-small cell lung cancer (NSCLC) and 48.6% in non-squamous patients [2]. - The company plans to initiate at least eight Phase III clinical trials for HLX43, indicating a strong commitment to advancing its development in lung cancer [2][7]. Group 3: Competitive Landscape - Other companies, including Kintor Pharmaceutical, 3SBio, and Innovent Biologics, are focusing on PD-1 bispecific antibodies, while Junshi Biosciences is leading in the PD-L1 ADC space [4][5]. - Kintor plans to submit its PD-1/VEGF bispecific antibody for FDA approval by Q4 2025, while Innovent is collaborating with Takeda on a new generation immune therapy [6]. Group 4: Financial Considerations - Junshi Biosciences reported a revenue of 2.82 billion yuan in the first half of the year, a 2.7% increase, with a net profit of 390 million yuan, raising concerns about funding future clinical trials which could cost around $200 million each [7].

Core Viewpoint - The Hong Kong medical sector is experiencing a strong performance, with the CSI Hong Kong Stock Connect Medical Theme Index rising by 2.19%, driven by leading stocks such as BeiGene and Ping An Good Doctor [1][2]. Group 1: Market Performance - The Hong Kong medical ETF (159366) has increased by over 2%, and over the past three months, it has accumulated a rise of 1.74% as of November 11, 2025 [1][2]. - The CSI Hong Kong Stock Connect Medical Theme Index includes 50 listed companies in the medical device, medical services, and pharmaceutical sectors, reflecting the overall performance of the medical sector within the Stock Connect [2]. Group 2: Company Performance - BeiGene reported a total revenue of $1.4 billion for Q3, marking a 41% year-on-year increase, with a GAAP net profit of $125 million, reversing a loss from the previous year [4]. - The innovative drug sector is showing strong growth, with a 23.34% increase in revenue year-on-year, and CXO companies seeing a 55.90% increase in net profit [4]. Group 3: Market Trends - The CRO service market in China is projected to grow from 52.2 billion yuan in 2020 to 87.8 billion yuan by 2024, with a compound annual growth rate (CAGR) of 13.9% [3]. - The overall performance of the pharmaceutical and biotechnology sector has been under pressure, with a decline in revenue and net profit by 1.9% and 4.8% respectively for the first three quarters of 2025 [4].

Group 1: Economic Overview of the Greater Bay Area - The Greater Bay Area, covering less than 0.6% of China's land area, generates approximately 1/9 of the national economic output, showcasing its high economic vitality [1] - The region has the highest density of listed companies in China, with 813 A-share listed companies in the nine mainland cities [1] Group 2: Innovation and R&D Investment - The Greater Bay Area's listed companies have significantly increased their R&D investments, totaling 237.31 billion yuan in the first three quarters of this year, a year-on-year increase of 9.69%, accounting for 20.69% of all A-share companies' R&D expenses [2] - BYD leads in R&D spending among A-share companies with 43.75 billion yuan, focusing on advanced technologies in the electric vehicle sector [2] Group 3: AI and Technology Development - TCL Huaxing is developing an AI architecture that enhances product development and quality control capabilities [3] - Daotong Technology has maintained a high R&D expense ratio of 15% to 20%, resulting in a 61.81% year-on-year increase in net profit for the first three quarters of 2025 [3] Group 4: Industry Upgrades and New Sectors - The Greater Bay Area is becoming a leader in new production capabilities, with breakthroughs in autonomous driving, low-altitude economy, and robotics [4] - Companies like WeRide and Pony.ai are expanding their operations globally, with WeRide holding licenses in seven countries [4] Group 5: International Expansion - In the first half of 2025, listed companies in the Greater Bay Area achieved overseas revenue of 955.60 billion yuan, representing 19.5% of all A-share companies' overseas revenue [7] - BYD's overseas revenue reached 135.36 billion yuan, marking a 50.49% year-on-year increase, as the company accelerates its international expansion [7] Group 6: Financial Empowerment and Future Development - The upcoming "2025 Greater Bay Area Technology and Financial Innovation Development Conference" aims to explore new paths for the integration of technology and finance, enhancing the region's role as an international technology innovation center [10][13]

Group 1 - The Hong Kong innovative drug sector experienced a strong performance, with companies like 3SBio and BeiGene rising by 6%, and others like InnoCare and CanSino Biologics increasing by 4.36% and 3.72% respectively, contributing to a 2% rise in the Hang Seng Pharmaceutical ETF [1] - BeiGene reported a total revenue of $1.4 billion for Q3, marking a 41% year-on-year increase and achieving a historical high for the same period, with a GAAP net profit of $125 million, reversing previous losses [1] - The negotiation for the 2025 National Basic Medical Insurance Drug List and the pricing discussions for innovative drugs in commercial insurance were completed last week, with expectations of active business development transactions in November and December, coinciding with major industry conferences [1] Group 2 - The Hong Kong Central Enterprise Dividend ETF saw a rise of over 1%, accumulating an 11% increase since September 26, indicating renewed investor interest in high-dividend assets as year-end approaches [1] - The Central Enterprise Dividend ETF includes major stocks such as COSCO Shipping Holdings, Orient Overseas International, CITIC Bank, China Construction Bank, China National Offshore Oil Corporation, and PetroChina [2] - The Hang Seng Pharmaceutical ETF, representing the global pharmaceutical industry chain, increased by 2.85%, with top-weighted stocks including BeiGene, WuXi Biologics, InnoCare, China National Pharmaceutical Group, and 3SBio [2]

Core Viewpoint - The Hong Kong stock market for innovative drugs is experiencing a rebound, with significant trading activity and price increases in related ETFs and stocks [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a price increase of over 3%, surpassing the 20-day moving average, with a trading volume exceeding 2 billion yuan within the first half hour of trading [1]. - Major constituent stocks have shown strong performance, with BeiGene leading with a gain of over 7%, reporting a quarterly revenue of 1.4 billion USD, a 41% increase year-on-year, and a GAAP net profit of 125 million USD, reversing a loss from the previous year [3]. Group 2: Market Trends and Analysis - Recent adjustments in the innovative drug sector have been deemed sufficient in both time and magnitude, with historical data indicating an average correction duration of 30-40 days and a typical decline of around 20% [3]. - The current adjustment has lasted nearly a quarter, with the index down over 20%, suggesting a potential for recovery as institutional investors prepare for next year's allocations [3]. Group 3: Investment Opportunities - CICC highlights a clear trend of Chinese innovative drugs going global, supported by ongoing drug review reforms and favorable domestic conditions, marking a shift from imitation to innovation [4]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) is recommended as a primary investment vehicle, tracking the Hang Seng Stock Connect Innovative Drug Select Index, which boasts three key advantages: purity in focus on innovative drugs, significant weight in leading companies, and controlled risks through liquidity management [4][5]. - The ETF has achieved a fund size exceeding 2 billion yuan and has the highest liquidity among similar ETFs, with an average daily trading volume of 474 million yuan since its inception [5].

Core Viewpoint - 康方生物 (09926.HK) experienced a nearly 5% increase in stock price, reaching 119.9 HKD with a trading volume of 310 million HKD [1] Group 1 - The stock price of 康方生物 rose by 4.72% [1] - The current trading price is 119.9 HKD [1] - The total trading volume amounted to 3.1 billion HKD [1]

Core Viewpoint - The A-share and Hong Kong stock markets for innovative drugs opened high and continued to rise, indicating a positive trend in the sector [1] Group 1: Market Performance - The Hong Kong innovative drug ETF (159567) saw an increase of approximately 3.02% as of 10:00 AM, with all constituent stocks performing well, including leading gains from companies like BeiGene, InnoCare Pharma, and CanSino Biologics [1] - Since November, the ETF has not experienced any net outflow of funds, accumulating a total of 726 million yuan in inflows during the month [1] Group 2: Industry Trends - Institutions indicate that the pharmaceutical sector has undergone a significant structural repair trend after a prolonged period of valuation adjustment, with continued business development (BD) in innovative drugs expected in the second half of the year [1] - The trend of interest rate cuts by major global central banks is anticipated to further enhance the valuation of the innovative drug sector [1] Group 3: Investment Opportunities - The Hong Kong innovative drug ETF (159567) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, aiming to reflect the operational characteristics of listed companies in the innovative drug field within the Stock Connect scope [1] - Retail investors can also access the Hong Kong innovative drug ETF through linked funds (Class A: 023929, Class C: 023930) to capitalize on the upward opportunities in the sector [1]